<DOC>
	<DOCNO>NCT01611948</DOCNO>
	<brief_summary>Cannabis widely use illicit drug United States , worldwide , 1 10 user estimate meet diagnostic criterion cannabis dependence . Avoidance withdrawal symptom ( e.g. , disturbance mood , sleep , crave ) common relapse precipitant . Cannabis use also impair executive cognitive function thereby increase vulnerability relapse reduce ability benefit behavioral therapy . There pharmacological treatment cannabis dependence , despite large number afflict individual limitation behavioral therapy remediate withdrawal associate high rate treatment failure . The primary aim clinical trial evaluate efficacy safety novel neurokinin1 ( NK1 ) receptor antagonist , aprepitant ( Emend ) , ( 125mg/day ) , outpatients current cannabis dependence . The main hypothesis test evaluate relative efficacy aprepitant 125 mg/d vs. placebo reduce cannabis withdrawal symptom cannabis dependent outpatient , specifically anxiety , mood , crave sleep .</brief_summary>
	<brief_title>Treatment Cannabis Withdrawal Dependence</brief_title>
	<detailed_description>This study Phase II , single-site , 8-week , randomize , double-blind , placebo-controlled , parallel group comparison aprepitant ( 125 mg/d ) placebo . Subjects 100 outpatient seek treatment current cannabis dependence clinically significant medical psychiatric disorder ( include substance use disorder positive drug screen substance cannabis nicotine ) . All subject receive weekly manual-guided abstinence-oriented counseling facilitate show drug effect beyond available therapy ( Weeks 0-8 ) . Research assessment marijuana use withdrawal drug safety tolerability occur weekly treatment phase 8-week study . Post treatment follow-up assessment occur Weeks 9 12 . Neuropsychological test occur Weeks 0 4 8 . Specific Aim 1 : To evaluate relative efficacy aprepitant 125 mg/d vs. placebo reduce cannabis withdrawal symptom cannabis dependent outpatient , include anxiety , mood , crave sleep symptom . Specific Aim 2 : To evaluate relative efficacy aprepitant 125 mg/d vs. placebo reduce marijuana use cannabis dependent outpatient . Specific Aim 3 : To evaluate relative efficacy aprepitant 125 mg/d vs. placebo reduce cannabis related impairment executive function cannabis dependent outpatient .</detailed_description>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<criteria>Males female 1870 year age Meets DSM IV criterion current cannabis dependence Seeking researchbased outpatient treatment cannabis dependence involve daily oral medication Smoked MJ daily least 25 day per month 90 day prior randomization Current cannabis use verify positive urine test &gt; 50 ng/ml At least 2year history regular MJ use Willing able give inform consent Abstinent cannabis 2 day time randomization Currently meet DSM IV criterion dependence substance , urine drug screen positive substance , cannabis nicotine Meets DSM IV criterion major AXIS I disorder cannabis nicotine dependence , Active suicidal ideation Significant medical disorder increase potential risk interfere study participation , Females pregnant , nurse sexually active childbearing potential refuse use doublebarrier method birth control study 4 week study termination Ongoing treatment medication may affect study outcome , Use CYP3A4 strong inhibitor ( e.g. , ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir ) CYP3A4 moderate inhibitor ( e.g. , diltiazem ) within 2 week period prior study drug administration within 5 halflives respective medication , whichever longer , study conclusion . Consumption grapefruit grapefruit product least 2 week prior study drug administration study conclusion . Ongoing treatment medication primarily metabolize CYP3A4 may increase plasma concentration coadministered aprepitant , pimozide , terfenadine , astemizole cisapride corticosteroid , well benzodiazepine include midazolam , alprazolam , triazolam . Ongoing treatment medication primarily metabolize CYP2C9 ( e.g. , warfarin , tolbutamide ) . Use drug ( e.g. , rifampin , carbamazepine , phenytoin ) herbal supplement ( e.g. , St John 's wort ) induce CYP3A4 activity may result reduce plasma concentration aprepitant decrease efficacy aprepitant . Inability understand and/or comply provision protocol consent form .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>